Randomised clinical trial: A placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 5, 2015, Pages 504-514

  Rutgeerts, P ^a   Feagan, B G ^b   Marano, C W ^c   Padgett, L ^c   Strauss, R ^c   Johanns, J ^c   Adedokun, O J ^c   Guzzo, C ^c   Zhang, H ^c   Colombel, J F ^d,e   Reinisch, W ^f   Gibson, P R ^g   Sandborn, W J ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g ALFRED HOSPITAL   (Australia)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; PLACEBO; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELLULITIS; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MAYO SCORE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TUBERCULOSIS; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLITIS, ULCERATIVE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938550662     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13291     Document Type: Article

References (20)

1. Sandborn WJ, van Assche G, Reinisch W, et al,. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
3. ® (Golimumab) Prescribing Information. Horsham, PA: Janssen Biotech Inc, 2013.
4. Kay J, Matteson EL, Dasgupta B, et al,. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 964-75.
5. Keystone E, Genovese MC, Klareskog L, et al,. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010; 69: 1129-35.
6. Emery P, Fleischmann RM, Moreland LW, et al,. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
7. Smolen JS, Kay J, Doyle MK, et al,.; for the GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21.
8. Kremer J, Ritchlin C, Mendelsohn A, et al,. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010; 62: 917-28. Erratum in Arthritis Rheum. 2010;62:3130.
9. Braun J, Deodhar A, Inman RD, et al,. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012; 71: 661-7.
10. Kavanaugh A, van der Heijde D, McInnes IB, et al,. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012; 64: 2504-17.
11. Sandborn WJ, Feagan BG, Marano C, et al,. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.
12. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317: 1625-9.
13. D'Haens G, Sandborn WJ, Feagan BG, et al,. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
14. Sandborn WJ, Feagan BG, Marano C, et al,. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.
15. Irvine EJ, Feagan B, Rochon J, et al,. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.
16. Zhuang Y, Xu Z, Frederick B, et al,. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther 2012; 34: 77-90.
17. Zhou H, Jang H, Fleischmann RM, et al,. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007; 47: 383-96.
18. Targan SR, Hanauer SB, van Deventer SJH, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
19. Weinblatt ME, Bingham CO, Mendelsohn AM, et al,. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013; 72: 381-9.
20. Reinisch W, Sandborn WJ, Hommes DW, et al,. Adalimumab for the induction of clinical remission in moderately to severely active ulcerative colitis; results of a randomized controlled trial. Gut 2011; 160: 780-7.